Effect of Dexmedetomidine on Hemodynamic Stability in Carotid Endarterectomy: Reduced Norepinephrine Use and Propofol Dosing Via Central Sympatholytic Action
Does the Co-administration of Dexmedetomidine Improve Hemodynamic Stability During Carotid Endarterectomy (CEA) Under General Anaesthesia? A Single-Centre Prospective Randomized Controlled Trial.
Objective and Selection We refer to our research project as the "research project" in this information sheet. If you participate, you will be a participant.
In this research project, we aim to investigate the effect of the medication dexmedetomidine on blood pressure during surgery on your carotid artery. We are inviting you because all individuals undergoing carotid artery surgery may participate.
General Information Due to your narrowing of the carotid artery, you require a planned procedure under general anesthesia. During this, your circulatory system and heart function will be continuously monitored through ongoing measurements to constantly track your condition. At the start of general anesthesia, heart rate, blood oxygen levels, and blood pressure will be monitored. Strong painkillers and anesthetic agents will then be administered for the general anesthesia. Additional medications will be given to maintain the anesthesia. Your condition will be closely and continuously monitored throughout the general anesthesia. At the end of the surgery, the anesthetic agents will be gradually reduced, allowing you to awaken from the anesthesia. In this context, we want to examine whether the additional administration of dexmedetomidine during carotid artery surgery reduces blood pressure fluctuations that may occur during such anesthesia.
The medication dexmedetomidine is approved for the Swiss market by Swissmedic and is commonly used today in many areas of anesthesia and intensive care medicine. It is even administered to pediatric patients in anesthesia. The goal of continuous dexmedetomidine administration during surgery is twofold: to reduce the need for other anesthetic agents while simultaneously minimizing blood pressure fluctuations that may arise during different surgical phases.
The scientific question is: Does additional administration of dexmedetomidine influence the intraoperative hemodynamic course and thus the clinical outcome after surgery? The study will be conducted over approximately 24 months at Inselspital Bern (single-center) with 44 patients. We are conducting this study in accordance with Swiss laws and all internationally recognized guidelines. The responsible cantonal ethics committee (KEK Bern, Murtenstrasse, Bern) has reviewed and approved the study. A description of this study is also available on the website of the Federal Office of Public Health: www.kofam.ch.
- Procedure The planned surgery will be performed independently of this study. Upon the patient's arrival in the operating room, they will be randomly assigned to one of two groups. One group will serve as the control group and receive standard general anesthesia according to our current hospital guidelines. The second group will receive the standard anesthesia plus the study medication dexmedetomidine in a precisely defined dose. Group allocation will be randomized and blinded (not disclosed to participants). The number of patients in both groups will be equal. Both groups will be treated and monitored in accordance with the recommendations and standards of the Department of Anesthesia and Pain Medicine at Inselspital Bern, as well as those of the Swiss Society for Anaesthesiology and Perioperative Medicine (SSAPM). Hemodynamic and cardiac function parameters will be closely monitored and recorded for all study participants. These data will be collected by the attending anesthesiologist.
At a precisely defined time point during the surgery (achievement of "burst suppression"), administration of the study medication will be stopped, and anesthesia will be adjusted according to surgical progress. After emergence from general anesthesia, you will be immediately assessed and then transferred to the recovery unit. During your stay on the recovery unit, circulatory parameters and your neurological status will be assessed at regular intervals.
Prior to transfer to the regular ward the following day, a questionnaire regarding your neurological status will be completed, and all medications administered during your recovery unit stay will be recorded. The study will then be finished for all participating patients.
調査の概要
状態
条件
詳細な説明
Hemodynamic stability is paramount during, and after carotid endarterectomy (CEA). Maintenance of cerebral perfusion pressure is required before, and during cross-clamping of the internal carotid artery (ICA) to prevent ischemia. After declamping, arterial hypertension must be avoided to prevent cerebral hyperperfusion syndrome (CHS), a rare, but serious complication after cerebral revascularisation procedures. CHS is associated with increased arterial blood pressure and characterised by headaches, neurological deficits, and seizures not caused by cerebral ischemia.
Recently, our group has demonstrated the significant propofol-sparing effect of the centrally acting alpha agonist dexmedetomidine during CEA. We also found significantly decreased requirements for the vasopressor norepinephrine, which may be well explained by the propofol sparing effect of dexmedetomidine in addition to its peripheral alpha-agonistic action (5).
Dexmedetomidine is known to exert a biphasic effect on arterial blood pressure (ABP); at higher concentrations, or when administered as an intravenous bolus, dexmedetomidine increases vascular resistance via peripheral alpha-adren-ergic receptors. After prolonged administration, and at lower concentrations, its central sympatholytic effects prevail (6-8), which may predispose dexmedetomidine as a well-suited adjunct to general anaesthesia for CEA. Recently, low-dose dexmedetomidine has been found to prevent CHS after stenting of the ICA (9).
In addition to its favorable hemodynamic profile, other beneficial effects of dexmedetomidine for CEA have been reported. Frequently, patients undergoing CEA have suffered recent stroke, which itself represents a high risk of delirium (POD) (10). In 700 elderly patients undergoing non-cardiac interventions8, low-dose dexmedetomidine was found to reduce the incidence of delirium from 23% to 9%. Moreover, there is growing evidence for neuroprotective effects of dexmedetomidine in the context of ischemia and reperfusion5,6 Proposed mechanisms include modulation of neuroinflammation, apoptosis, oxidative stress, and synaptic plasticity via the α2-adrenergic receptor (11).
Our previous study was designed to measure the effects of dexmedetomidine on intraoperative requirements of propofol. While the decreased requirements for norepinephrine were clinically significant, it was not defined as primary outcome measure. Also, most of the parameters have been collected only during the immediate perioperative period. The only assessment on postoperative day 1 was CAM-ICU for delirium.
The main purpose of the present follow-up study is to measure the effects of dexmedetomidine on systemic haemodynamics during, and after CEA, with a particular focus on 1) maintenance of cerebral perfusion pressure before and during cross-clamping of the ICA and 2) maintenance of an upper limit of systolic arterial blood pressure for prevention of CHS.
To evaluate the haemodynamic stability during and after CEA with co-administration of dexmedetomidine compared to a standard therapy.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前：Christian cv Vetter, MD
- 電話番号：+41 (0) 31 664 37 76
- メール：christian.vetter@insel.ch
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- age ≥18 years
- ASA physical status 1-4
- written informed consent provided.
Exclusion Criteria:
- Age <18 years, Rapid sequence induction needed for surgery, higher grade atrioventricular block without pacemaker, severe hypovolaemia or bradycardia, uncontrolled hyper or hypotension, hypersensibility concerning the active substance Dexmedetomidine or any other component, serve liver disease, known malignant hyperthermia, cardiovascular instability or severe heart failure (EF ≤ 30% or > NYHA III), limited peripheral autonomic activity, pregnancy, rejection or lack of consent of the patient.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Co-Administration of Dexmedetomidine
the participant in this group will recieve the standard anaesthesia care and in addition dexmedetomidine, First with a bolus of 0.4üg/kg over 10 min and then with a perfusor 0.4üg/kg/h during the hole operation
|
Standard anaesthesia with propofol with co-administration of Dexmedetomidine and Propofol with Dexmedetomidine (bolus 0.4 mcg/kg over 10 minutes followed by an continuous infusion with 0.4 mcg/kg/h until burst suppression will be reached) in conjunction with electrophysiological studies (somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs))
|
|
他の：control group
the control group recieve the standard medical care during th operation
|
Standard anaesthesia with Propofol in conjunction with electrophysiological studies (somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs)).
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary study outcome
時間枠：2 years
|
Primary study outcome are to evaluate the dose of Noradrenaline during CEA with EEG burst suppression (measured and interpreted by the anaesthes¬iologist) for the co-administration of Dexmedetomidine in combination with Propofol compared to Propofol alone as the standard therapy.
|
2 years
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2025-00592 (その他の識別子：Kantonale Ethikkommision Bern, Murtenstrasse 10, 3010 Bern, Switzerland)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。